Stockpolly
Search
IMRX · NASDAQ · Biotechnology

Immuneering (IMRX)

Develops oral Deep Cyclic Inhibitors for MAPK-pathway-driven cancers.

$5.02
At close+0.17 (+3.61%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000100
Gross profit000000000−100
141615151518151515131519
Research & development101211111115111011910,64514
44444444554,6825
General & administrative40444044554,6825
Other expenses000000000−1−15,3130
Operating income−14−16−15−15−15−19−15−15−15−14−15−19
111111000222
Interest income111110000−41411
Other non-operating income0−1000−100000−2
Income before tax−13−15−14−14−15−18−15−14−15−12−13−17
Net income from continuing operations−13−15−14−14−15−18−15−14−15−12−13−17
Other adjustments000000000000
Net income−13−15−14−14−15−18−15−14−15−12−13−17
EPS, basic−$0.43−$0.52−$0.49−$0.47−$0.49−$0.58−$0.42−$0.40−$0.38−$0.18−$0.21−$0.27
EPS, diluted−$0.43−$0.52−$0.49−$0.47−$0.49−$0.58−$0.42−$0.40−$0.38−$0.18−$0.21−$0.27
Weighted average shares, basic292929303031363640656565
Weighted average shares, diluted292929303031363640656565
EBITDA−14−15−15−15−15−18−15−15−15−14−15−17
Depreciation & amortization000000000000
EBIT−14−15−15−15−15−18−15−15−15−14−15−17